Biopharmaceutical company SAB Biotherapeutics (SAB) on Saturday provided an update of the interim analysis of the defined safety and efficacy data of SAB-185 in the phase 2 part of the ACTIV-2 study, following an independent Data Safety Monitoring Board (DSMB ) review.
The company said SAB-185 is a fully human, targeted, broadly neutralizing polyclonal antibody drug candidate for the treatment of non-hospitalised patients with mild to moderate COVID-19.
SAB-185 is being tested in the ACTIV-2 study, which is funded and carried out by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the NIH (National Institutes of Health, USA) - in collaboration with the AIDS Clinical Trials Group.
According to the company, the lower and higher doses of SAB-185 tested in phase 2 met the pre-defined efficacy target for transition to phase 3 and were shown to be safe in the interim analysis. The NIAID and SAB researchers are currently in the process of determining the preferred dose for the Phase 3 trial. SAB-185 is being transferred to phase 3 study upon meeting defined promotion criteria.
SAB added that the Phase 3 portion of the ACTIV-2 study is a randomized, open-label, active comparator-controlled, adaptive platform study to evaluate the clinical safety and efficacy of SAB-185 compared to active control treatment with a monoclonal antibody in patients with mild to moderate COVID-19, who have a higher risk of hospitalisation. The primary outcome measured the safety and non-inferiority to prevention of a composite endpoint defined as either hospitalisation or death from any cause by study day 28.
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children